RVNC · Revance Therapeutics
Acquired Company
Crown Laboratories completed the acquisition of Revance Therapeutics on 2/6/2025 following a tender offer at $3.65 per share, with the transaction finalized via a second-step merger.
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
1222 DEMONBREUN STREET, NASHVILLE, TN, UNITED STATES, 37203, Suite 1001, Tennessee, 37203, USA
BIOTECHNOLOGY
HEALTHCARE
Market Cap
381M
52 Wk Range
$0.00 - $0.00
Previous Close
$3.65
Open
$3.65
Volume
N/A
Day Range
$3.65 - $3.65
Enterprise Value
N/A
Cash
58.59M
Avg Qtr Burn
-41.09M
Insider Ownership
8.56%
Institutional Own.
87.45%
Qtr Updated
Sep 30th 2024